Gabelli Funds’s Acadia Pharmaceuticals ACAD Stock Holding History

Gabelli Funds’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,000	Closed	-$216K	–	1136
2023 Q2	$216K	Buy	+9,000	New	+$200K	﹤0.01%	1012
2022 Q2	–	Sell	-9,000	Closed	-$218K	–	1393
2022 Q1	$218K	Hold	9,000	–	–	﹤0.01%	1236
2021 Q4	$210K	Buy	+9,000	New	+$181K	﹤0.01%	1256

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Gabelli Funds's ACAD Position: Q3 2023 in Review

Gabelli Funds sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 9,000 shares — an estimated $216K sold.

Gabelli Funds first reported a position in ACAD in Q4 2021 and held it in 3 quarters. The position peaked at $218K in Q1 2022. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

Gabelli Funds reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Gabelli Funds sold 9,000 Acadia Pharmaceuticals shares in Q3 2023, an estimated $216K.
Gabelli Funds first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 3 quarters.
Gabelli Funds's Acadia Pharmaceuticals position peaked at $218K in Q1 2022.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Gabelli Funds's 13F filing for Q3 2023, filed 8 Nov 2023.